The functional and quality-of-life benefits of transcatheter aortic valve replacement (TAVR) have not been established.
A ortic stenosis (AS) is the most common valvular heart disease in developed countries, and it affects 2% to 3% of adults older than 75 years (1) . With the aging population, the potential effect of symptomatic severe AS on functional status, quality of life, and health care expenditure is considerable (2, 3) . Surgical aortic valve replacement (SAVR) is the treatment of choice that has been proved to decrease mortality rates and improve quality of life (4, 5) . However, approximately one third of older patients do not have surgery (6) . Without SAVR, older patients who are medically managed have nearly a 50% mortality rate at 1 year and high health care costs because of multiple hospitalizations and skilled nursing care utilization (2) .
In recent years, transcatheter aortic valve replacement (TAVR) has emerged as an alternative treatment for highrisk or inoperable patients with symptomatic severe AS. An estimated 290 000 older patients in Europe and North America are candidates for TAVR (7). Although the PARTNER (Placement of Aortic Transcatheter Valve) trial demonstrated improved quality of life over 1 year similar to SAVR among high-risk patients and superiority of TAVR to standard treatment among inoperable patients (8, 9), it is unclear whether such benefit is generalizable to real-world practice. Furthermore, recent reviews focused on adverse effects of TAVR, such as mortality rates and vascular complications (10 -13), whereas patients having TAVR may place greater value on functional status and quality of life than longevity (14) . Change in functional status and quality of life may better reflect patients' experiences with disease progression and treatment-related complications. However, repairing a single condition among several comorbid conditions may not meaningfully restore patients' functional ability.
A careful evaluation of current evidence on the functional and quality-of-life benefits of TAVR will provide valuable information to physicians and patients to guide informed decision making. Therefore, we conducted a systematic review to evaluate the effect of TAVR on various measures of functional status and quality of life.
METHODS

Data Sources and Study Selection
We conducted a systematic search of MEDLINE, EMBASE, and the Cochrane Central Register of Con-trolled Trials between 1 January 2002 and 30 September 2013 using the keywords "transcatheter" and "aortic valve" and no language restrictions to identify full-length articles on prospective studies that reported functional status or quality-of-life outcomes of TAVR (Appendix 1, available at www.annals.org). We also manually searched included references of published reviews (12, 13, 15-23).
Studies were eligible if they reported 1 of the following measures of functional status and quality of life at baseline and at least 6 months after TAVR: the NYHA (New York Heart Association) functional class; the Short Form (SF)-12/36 Health Survey physical component summary (PCS) and mental component summary (MCS) scores (24, 25); and other measures of functional status and quality of life, including the 6-minute walk test (26), Activities of Daily Living (ADL) (27), EuroQol-5D (28), Kansas City Cardiomyopathy Questionnaire (29), and Minnesota Living With Heart Failure Questionnaire (30). Studies were excluded if they were nonhuman studies, reviews, commentaries, case reports, or abstracts; the intervention was not TAVR; and no primary outcomes were reported at 6 months or later. When more than 1 study originated from the same patient population, studies with a longer follow-up were included (8, 9, 31-42).
Two investigators independently assessed abstracts and full-text articles for eligibility, and disagreement was resolved by a third reviewer. Our systematic search identified 60 observational studies with or without comparison groups and 2 randomized, controlled trials (Appendix Figure 1 , available at www.annals.org).
Data Extraction and Quality Assessment
Two investigators independently used a standardized form to extract the following patient-and treatmentrelated characteristics by treatment groups (TAVR, SAVR, or conservative treatment [defined as medical treatment with or without balloon aortic valvuloplasty]): sample size, mean age, sex, type of device (Sapien [Edwards, Irvine, California], CoreValve [Medtronic, Minneapolis, Minnesota], or Cribier-Edwards [Edwards]), approach (transfemoral, transapical, transaxillary, transaortic, subclavian, or carotid), the Society of Thoracic Surgeons (STS) score, the logistic European System for Cardiac Operative Risk Evaluation, mean aortic valve area, and mean aortic valve gradient. We collected the following primary outcomes (minimal clinically important difference) (Appendix Table  1 , available at www.annals.org): NYHA class (Ն1 class) (43); SF-12/36 PCS and MCS scores (Ն2.5 points) (44); 6-minute walk test distance (Ն50 m) (26); ADL limitations (Ն1 limitation); EuroQol-5D score (Ն0.074 points) (45); Kansas City Cardiomyopathy Questionnaire score (Ն ure Questionnaire score (Ն5 points) (47). With the exception of NYHA class and Minnesota Living With Heart Failure Questionnaire score, greater values score indicate better function. We also extracted all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and rehospitalization as secondary outcomes.
We modified the Newcastle-Ottawa Scale (48) to evaluate studies for the following quality domains (Appendix Table 2 , available at www.annals.org): representativeness of source population, selection of the comparison patients, adjustment for the difference in functional outcome at baseline, adjustment for the difference in left ventricular systolic function at baseline, assessment of functional outcomes, and adequacy of follow-up.
Data Synthesis and Analysis
Because of poor quality of included studies and substantial unexplained heterogeneity, we summarized the change in primary outcomes over 6 to 11 months, 12 to 23 months, 24 to 35 months, and 36 months or more descriptively (Appendix 2, available at www.annals.org) without pooling individual study estimates. When there are few high-quality studies, a DerSimonian-Laird random-effects estimate (49) can be misleading and its 95% CI underestimates the uncertainty of treatment effects. Thus, we presented the range of observed mean changes and displayed the variation in forest plots. For secondary outcomes, we combined the individual study estimates using a DerSimonian-Laird random-effects model and presented the range. Analyses were done in Stata, version 11.2 (StataCorp, College Station, Texas). A 2-sided P value less than 0.05 was considered significant.
Role of the Funding Source
This research was supported by the Health Resources and Services Administration and Health Resources in Action. The funding sources had no role in the design of the study; collection, analysis, or interpretation of the data; or the decision to submit the manuscript for publication.
RESULTS
Patient Characteristics in Included Studies
We identified 60 observational studies (56 studies of pre-and post-TAVR comparison and 4 studies of TAVR versus surgical or conservative treatment) and 2 randomized, controlled trials that included a total of 11 205 patients treated with TAVR. Clinical characteristics of patients treated with TAVR varied widely across studies (Table and Appendix Table 3 , available at www.annals .org). In the 56 observational studies of pre-and post-TAVR comparison, the mean age was 73 to 93 years, 14% to 94% of participants were women, STS-predicted 30-day mortality rates were 5% to 25%, and 54% to 100% of participants had NYHA class III or IV symptoms at baseline. In 4 observational studies with comparison groups, patients treated with TAVR tended to be older and have greater STS-predicted mortality rates than SAVR patients, and a greater proportion of TAVR patients had NYHA class III to IV symptoms. Patients treated with TAVR were younger and had lower STS-predicted mortality rates than patients who were treated conservatively, but the proportion of those with NYHA class III to IV symptoms was similar. Nonetheless, there was considerable overlap in clinical characteristics among patients treated with TAVR, SAVR, or conservative treatment. Many observational studies included patients who were at lower risk and less symptomatic than patients in the PARTNER trial.
Quality of Included Studies
Our assessment of study quality revealed that most were small pre-and post-TAVR comparison observational studies that were prone to a high risk of bias (Appendix Table 4 and Appendix Figure 2 , available at www.annals .org). The small number of head-to-head comparison studies (6 of 62 studies) posed major challenges in drawing definitive conclusions about the functional benefits of TAVR from the available evidence. If functional outcomes were to decline over time without TAVR, the lack of a group that was treated conservatively would underestimate the benefits of TAVR. In addition, the lack of independent assessors of functional outcomes (45 studies), especially when a subjective interpretation of patient responses was possible, may have led to a conclusion favoring TAVR. Of 6 head-to-head comparison studies, 2 did not adjust for baseline imbalance in important prognostic factors. Representativeness of included patients was limited or unclear in 21 studies. The pre-and post-TAVR comparison among survivors and the presence of nonnegligible loss to follow-up (12 studies) may have also overestimated the benefits of TAVR.
Change in NYHA Class
Eight studies (34, 50 -56) qualitatively reported improvement in NYHA class after TAVR. In 51 studies with quantitative data, a substantial variation in the mean change in NYHA class was seen (Figures 1 and 2 and Appendix Figure 3 , available at www.annals.org). In most studies, there was an average improvement of 1 NYHA class after TAVR at 6 to 11 months (range, Ϫ0.8 to Ϫ2.1 classes), 12 to 23 months (range, Ϫ0.8 to Ϫ2.1 classes), 24 to 35 months (range, Ϫ1.2 to Ϫ2.6 classes), and 36 months or more (range, Ϫ1.2 to Ϫ1.6 classes). However, several studies (32, 37, 62, 74, 76, 80, 94, 97) showed a mean change of less than 1 NYHA class and a lower 95% confidence limit near 0, indicating that a large proportion of patients did not improve after TAVR.
The NYHA class also improved with SAVR at 6 to 11 months (range, Ϫ1.5 to Ϫ1.7 classes), 12 to 23 months (range, Ϫ0.9 to Ϫ1.7 classes), and 24 months (Ϫ1.7 classes) (Figures 1 and 2) . The mean change was less than 1 NYHA class with conservative treatment (Figures 1 and  2) . Among patients who were treated conservatively, those who were treated with balloon valvuloplasty seemed to improve slightly more than those who only received medical treatment (40, 98, 99). 
SF-12/36 PCS and MCS Scores
One study (65) qualitatively reported improvement in SF-12 PCS and MCS scores over 12 months. In 8 studies that reported the mean change in SF-12/36 scores, large between-study heterogeneity was seen (Figures 3 and 4) . On average, the PCS score improved at 6 to 11 months (range, 6.3 to 18.4 points) and 12 months (range, 4.9 to 26.9 points) (Figure 3 ). After influential studies by Bekeredjian (60), Georgiadou (64) , and Taramasso (101) and their respective colleagues were excluded, the improvement was modest yet clinically important at 12 months. However, the improvement in MCS scores seemed smaller than the change in PCS score at 6 to 11 months (range, 2.0 to 13.3 points) and 12 months (range, 1.0 to 8.9 points) ( Figure 4) . In a few studies (9, 77, 91, 100), the lower 95% confidence limit was less than 2.5 points. It was evident that some patients did not have a clinically important improvement or even decrease in their MCS score.
The changes in SF-12/36 scores for SAVR and conservative treatment were only assessed in the PARTNER trial. Patients who had SAVR had clinically important improvements in PCS score of 7.1 points at 6 to 11 months and 5.6 points at 12 months (Figure 3) . The changes in MCS score were 3.9 points and 4.4 points, respectively ( Figure  4) . Patients who received conservative treatment had little improvement in their PCS and MCS scores.
Other Measures of Function and Quality of Life
Studies showed a clinically important improvement in the following disease-specific or physical functional mea- (74) . The results were less consistent in general health as measured by the EuroQol-5D (9, 71, 100) (Appendix Table 5 , available at www.annals.org).
Mortality, Cardiovascular Events, and Rehospitalization
The risk for all-cause mortality ranged from 0% to 28% at 6 to 11 months, 0% to 44% at 12 to 23 months, and 13% to 44% at 24 months or more (Appendix Table  6 , available at www.annals.org). For the corresponding periods, the ranges of risk were 0% to 18%, 0% to 24%, and 4% to 29% for cardiovascular mortality; 0% to 18%, 0% to 7%, and 0% to 9% for myocardial infarction; 0% to 18%, 0% to 13%, and 0% to 16% for stroke; and 1% to 55%, 7% to 34%, and 21% to 30% for rehospitalization. The results highlight the ongoing medical needs to prevent and treat these conditions even after TAVR.
DISCUSSION
Our systematic review shows considerable variation across 62 studies in the clinical characteristics of patients having TAVR and in the amount of improvement in functional outcomes and quality of life after TAVR. There was an overall trend that TAVR improved symptoms, physical function, and disease-specific measures of quality of life. However, the benefits in psychological dimension and general health measures were often small and inconsistent. This is valuable information for older patients with symptomatic severe AS whose goal may be to improve the quality of life and maintain functional independence rather than prolong the remaining life expectancy.
Since TAVR has become a treatment option for highrisk older patients, many studies have been conducted to understand the effectiveness and safety outcomes of this procedure, including total and cardiovascular mortality, vascular complications (such as myocardial infarction, stroke, pacemaker implantation, and renal insufficiency), and bleeding complications. These efficacy and safety end points have been summarized in recently published reviews (10 -13). Although these end points are essential to understanding the safety of TAVR and obtaining regulatory approval, they may not necessarily reflect the totality of the risks and benefits from the patients' perspective. Patientcenteredness can be enhanced by examining functional status and quality of life, which can reflect the patients' experience of disease-and treatment-related burden.
Nearly all studies that reported NYHA class as a measure of symptom severity and functional limitations showed an average improvement of at least 1 NYHA class over as many as 36 months. However, as evidenced by a heterogeneous distribution of individual study estimates and CIs, some patients had no improvement. Gotzmann and colleagues (33) found that 21% of 107 patients did not have an improvement or decline in NYHA class after TAVR. In another study of 76 patients, 30% reported no change or worsening functional status measured by the Duke Activity Status Index (102) despite successful TAVR, whereas most patients reported improved NYHA class (103) . Because of its subjective nature and poor correlation with objectively measured exercise capacity, it is questionable whether NYHA class is sensitive enough to capture the overall effect of severe AS and treatment on patients' quality of life and ability to perform routine daily activities (104, 105) . Therefore, NYHA class should be supplemented with other validated instruments of functional status and quality of life.
Only a few studies assessed other validated measures of functional status and quality of life over 12 months. Similar to NYHA class, clinically important changes were seen in other disease-specific measures (Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire) and physical dimension (SF-12/36 PCS, 6-minute walk test, and ADL). The improvement was less consistent and often smaller than what was considered clinically important in general health measures (EuroQol-5D) and psychological dimension (SF-12/36 MCS). Given the dismal prognosis of symptomatic severe AS without aortic valve replacement, these results suggest that TAVR alleviates symptoms and improves physical function and quality of life compared with conservative treatment.
This favorable evidence on the functional and qualityof-life benefits of TAVR should be interpreted cautiously with consideration of important limitations inherent in the body of literature. First, most studies did not include an independent comparison group that received an alternative treatment. This prohibited the assessment of the change in functional status due to TAVR in comparison with the natural change or change under an alternative treatment. On the basis of 6 head-to-head comparative studies included in our review (39 -42, 85, 98, 99, 106), TAVR seems to offer similar improvements in NYHA class and SF-12/36 PCS and MCS scores compared with SAVR. More comparative studies on functional outcomes and quality of life are needed to confirm these findings to help treatment decision making for patients and physicians. Second, substantial heterogeneity was found in terms of the clinical characteristics of patients treated with TAVR and the mean change in primary outcomes. Patients in many observational studies had lower surgical risk and less severe symptoms than patients in the PARTNER trial, which may indicate a wide variation in patient selection and TAVR practice across institutions and regions. Highly variable characteristics of patients, practice patterns, and methodological limitations may be responsible for the large heterogeneity of the treatment effect. Third, the improvement in primary outcomes seen from survivors would overestimate the overall benefits of TAVR if the immediate hazards associated with TAVR selectively removed frail patients who were the most susceptible to functional decline.
The mean change that is conditional on survival does not provide a global assessment of risks and benefits of TAVR. A novel approach to combine mortality and functional outcomes should be adopted to evaluate the overall treatment effectiveness in older adults.
Furthermore, the average improvement seen in a group of patients does not necessarily indicate the amount of benefit for each individual patient. We found evidence that a considerable proportion of patients worsened or did not have clinically meaningful improvement in functional status and quality of life after TAVR. Identifying patients who are most likely to have survival and functional benefits is critical to achieve optimum health outcomes and prevent avoidable harms. More research is needed to develop a better classification algorithm that predicts procedural success as well as long-term survival and functional benefits. Geriatric assessment and identification of frailty have been shown to predict postoperative complications and survival after cardiac surgery (107, 108) . Whether they are also useful in predicting long-term functional benefits from TAVR remains to be studied.
A few limitations in our systematic review deserve mention. The extent of unexplained between-study heterogeneity and variable methodological quality of the included studies may indicate the possibility of bias inherent in individual study estimates. To avoid underestimation of the degree of uncertainty in current literature, we did not pool individual study estimates of the change in NYHA class or SF-12/36 scores. In addition, high risk of bias in individual study estimates limited our ability to explore clinical heterogeneity of treatment effect by certain clinical characteristics. Because of the paucity of studies, our review provides limited evidence on other disease-specific measures, physical performance, or disability. Finally, despite our efforts to remove duplicate reports originating from the same population, some patients may have been included more than once.
On the basis of our review of current literature, we conclude that TAVR provides a clinically meaningful improvement in symptoms, physical function, and diseasespecific measures of quality of life compared with conservative treatment. The psychological or general health benefits seem to be modest. Considering the variable methodological limitations and risk of bias in the literature, we call for well-designed prospective studies of TAVR that evaluate long-term changes in functional status and quality of life in comparison with alternative treatments. Future research should examine the heterogeneity of treatment effectiveness for better patient selection by considering individual frailty status and vulnerability to treatment-related adverse effects. 
APPENDIX 2: COMPUTATION OF THE CHANGE IN PRIMARY OUTCOMES
We calculated the mean change ( change ) and SD ( change ) in primary outcomes over a follow-up period in each study, using the following equations: change ϭ follow-up Ϫ baseline and
where is the correlation coefficient between baseline and follow-up measures. From published papers (8, 31), we estimated the correlation coefficients for 6 to 11 months and 12 to 23 months: was 0.30 and 0.22, respectively, for the NYHA class (calculated from the Kansas City Cardiomyopathy Questionnaire score that is correlated with NYHA class [46]); 0.07 and 0.18, respectively, for the SF-12/36 PCS score; and 0.31 and 0.19, respectively, for the SF-12/36 MCS score. For the change in NYHA class from baseline to 24 months or more, we assumed that was 0.10.
6MWT ϭ 6-minute walk test; ADL ϭ Activities of Daily Living; EQ-5D ϭ EuroQol-5D; KCCQ ϭ Kansas City Cardiomyopathy Questionnaire; MLHFQ ϭ Minnesota Living With Heart Failure Questionnaire; NYHA ϭ New York Heart Association; SF ϭ Short Form; TAVR ϭ transcatheter aortic valve replacement. * In some cases, Ͼ1 study originated from the patient population. The follow-up duration was defined as the maximum number of months at which the exact number of patients with available outcome status could be calculated. When this was not reported, the mean or median duration was used. ‡ The proportion was approximated from a graph. § ST that includes balloon aortic valvuloplasty. Strict MT without balloon aortic valvuloplasty. NYHA ϭ New York Heart Association; SAVR ϭ surgical aortic valve replacement; TAVR ϭ transcatheter aortic valve replacement.
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